四環醫藥(00460.HK)2021年營收同比增長33.6% 全速推進醫美及生物製藥雙輪驅動戰略
格隆匯3月29日丨四環醫藥(00460.HK)公佈2021年度業績,期內集團實現來自持續經營業務收益32.91億元人民幣(單位下同),同比增長33.6%;毛利24.49億元,同比增長27.9%;研發開支8.68億元,同比增長19.0%,集團的研發投入持續加碼,推動集團製藥板塊的價值快速放大;公司擁有人應占溢利達4.17億元;每股基本盈利4.42分,宣派末期股息每股1.3分及特別現金股息每股9.5分。
公吿稱,收益增長主要由於集團的新業務板塊,醫美業務板塊取得收益3.99億元,同比增長1383.3%,主要是因為肉毒毒素樂提葆®實現上市銷售,對集團業績產生積極貢獻。
仿製藥業務板塊實現收益25.98億元,同比增長18.2%,顯示了重點監控目錄產品對集團的仿製藥業務的影響已進入尾聲,集團仿製藥板塊的業績已經正式進入上升通道。
2021年,對於集團也是特別的一年,是四環醫藥的拐點之年。在這一年內,集團全速推進醫美及生物製藥雙輪驅動戰略,成功實現從傳統仿製藥公司向領先創新藥及醫美公司的轉型。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.